These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2412028)

  • 1. Evidence for a central component to the hypotensive action of ketanserin in the dog.
    Mylecharane EJ; Phillips CA; Markus JK; Shaw J
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S114-6. PubMed ID: 2412028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypotensive actions of ketanserin in dogs: involvement of a centrally mediated inhibition of sympathetic vascular tone.
    Phillips CA; Mylecharane EJ; Markus JK; Shaw J
    Eur J Pharmacol; 1985 May; 111(3):319-27. PubMed ID: 2862048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms involved in the vasodilator action of 5-hydroxytryptamine in the dog femoral arterial circulation in vivo.
    Phillips CA; Mylecharane EJ; Shaw J
    Eur J Pharmacol; 1985 Jul; 113(3):325-34. PubMed ID: 2931286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.
    Bolt GR; Saxena PR
    Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
    McLennan PL; Taylor DA
    Eur J Pharmacol; 1984 Sep; 104(3-4):313-8. PubMed ID: 6499925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.
    Gradin K; Pettersson A; Hedner T; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S110-1. PubMed ID: 2412026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S105-9. PubMed ID: 2412025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of action of the hypotensive effect of ketanserin.
    Marwood JF; Stokes GS
    Clin Exp Pharmacol Physiol; 1984; 11(2):125-32. PubMed ID: 6086191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.
    Wenting GJ; Woittiez AJ; Man in't Veld AJ; Schalekamp MA
    Hypertension; 1984; 6(1):100-9. PubMed ID: 6319278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of ketanserin on blood pressure in rats].
    Sano M; Minami M; Togashi H; Yoshioka M; Tochihara M; Hirokami M; Saito H
    Nihon Yakurigaku Zasshi; 1985 Dec; 86(6):401-9. PubMed ID: 2419229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the in vivo and in vitro cardiovascular effects of four new analogues of ketanserin: implication of 5-HT2A and alpha1 adrenergic antagonism in their hypotensive effect.
    Orallo F; Tristan H; Garcia-Ferreiro T; De Francisco S; Masaguer C; Raviña E; Calleja JM; Cadavid I; Loza MI
    Biol Pharm Bull; 2000 May; 23(5):558-65. PubMed ID: 10823664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat.
    Pettersson A; Persson B; Henning M; Hedner T
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):43-7. PubMed ID: 6493349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.
    Conolan S; Quinn MJ; Taylor DA
    Br J Pharmacol; 1986 Sep; 89(1):129-35. PubMed ID: 3801767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of responses to sympathetic nerve stimulation and vasoconstrictor agents by SK&F 103829 in the feline mesenteric circulation.
    Taylor EM; Kaumann AJ
    Br J Pharmacol; 1994 Jan; 111(1):264-70. PubMed ID: 8012704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible central action of prazosin and ketanserin to cause hypotension.
    Copeland IW; Bentley GA
    J Cardiovasc Pharmacol; 1985; 7(5):822-5. PubMed ID: 2413287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of omega-conotoxin GVIA and tetrodotoxin on vasoconstrictions evoked by electrical stimulation and nicotinic receptor stimulation in canine isolated, perfused splenic arteries.
    Ren LM; Nakane T; Chiba S
    Br J Pharmacol; 1994 Apr; 111(4):1321-7. PubMed ID: 7913375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of antihypertensive action of ketanserin in man.
    Reimann IW; Frölich JC
    Br Med J (Clin Res Ed); 1983 Aug; 287(6389):381-3. PubMed ID: 6135489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin-induced vasoconstriction in the perfused canine femoral artery can be blocked in vivo by ketanserin.
    Meschig R; Breuer J; Arnold G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S56-9. PubMed ID: 2412060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.